-
- Jan 18, 2021
More optometrists diagnosing glaucoma
When it comes to diagnosing glaucoma, the role of the optometrist is growing, however, ophthalmologists overwhelmingly continue to be the providers initiating glaucoma treatment, according to a study.
Between 2007 to 2018, 303,440 patients received initial glaucoma care by ophthalmologists and 98,1…
-
- Jan 20, 2021
Phase 3 study of NOV03 for DED completes enrollment
The first of two Phase 3 studies evaluating NOV03 (perfluorohexyloctane; Bausch + Lomb) as a first-i... -
- Jan 20, 2021
Glaucoma compliance tool could help optimize patient adheren...
Using a compliance assessment tool, researchers were able to identify patient-specific factors assoc...
VIDEOS
- Jan 06, 2021
Surgical Pearls with Dr Matthew J. Marano: Case #14
-
Jan 06, 2021
Surgical Pearls with Dr Matthew J…
-
Jan 06, 2021
Surgical Pearls with Dr Matthew J…
-
Jan 06, 2021
Practice Pearls: Implementing…
-
Jan 06, 2021
Patient Education: Detecting…
-
Jan 06, 2021
Understanding the Link Between…
-
Jan 06, 2021
Teleophthalmology for Glaucoma
Jan 06, 2021
Teleophthalmology for Glaucoma
-
Patient Pearl: Talking with glaucoma patients…
Jan 06, 2021
-
Long-term studies of VEGF inhibitor use, Part 2
Dec 15, 2020
-
Long-term studies of VEGF inhibitor use, Part 1
Dec 15, 2020
Conference Roundup
- Jan 15, 2021
Among all ophthalmic meetings, there is one that stands out
Welcome to the Ophthalmic Project—a series of blogs and podcasts written and produced by Mark L. Dlugoss, senior contributing editor. The Ophthalmic Project will address trends, events, and observations in the world of ophthalmology. Dlugoss has about 25 years of experience…
Continuing Medical Education
Journal Scan
- Jan 18, 2021
More optometrists diagnosing glaucoma
When it comes to diagnosing glaucoma, the role of the optometrist is growing, however, ophthalmologists overwhelmingly continue to be the providers initiating glaucoma treatment, according to a study.
Between…
Trending Topics
- Jan 20, 2021
Phase 3 study of NOV03 for DED completes enrollment
The first of two Phase 3 studies evaluating NOV03 (perfluorohexyloctane; Bausch + Lomb) as a first-in-class investigational drug to treat the signs and symptoms of Dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) has been completely enrolled with a total of 599…
-
Myths of MicroPulse transscleral laser therapy
Jan 15, 2021
-
-
-
Resources
-
Eye Care Organizations
- American Academy of Ophthalmic Executives
- American Academy of Ophthalmology
- American Association for Pediatric Ophthalmology and Strabismus
- American Glaucoma Society
- American Society of Cataract and Refractive Surgery
- American Society of Ophthalmic Administrators
- Contact Lens Association of Ophthalmologists
- Cornea Society
- Medical Group Management Association
- The Retina Society
-
Eye Care Tools
- AAPOS Vision Screening App
- American Thyroid Association
- ASCRS MACRA Center
- Cataract Surgery Risk Calculation Tool
- Clinical Decision-Making Algorithms for Glaucoma
- Cornea Transplant Database
- Diagnostic Tools for Dry Eye Disease
- Marketing Ophthalmology Services to Boost Business
- Post-Refractive IOL Calculator
- Practice Tools
- PRK, LASIK and SMILE Treatment Steps Graphic
- Professional Contact Lens Fee Calculator
- RetinaTalk Forum
